7 Undervalued Biotechnology & Medical Research Stocks for Thursday, November 16
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Thursday, November 16 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Commentary & Analysis
Is Addex Therapeutics Ltd - ADR (ADXN) Stock a Good Investment?
Learn more about Addex Therapeutics Ltd - ADR's (ADXN) stock grades for Momentum and Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | ADXN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.2 | $579.1 | 5% |
|
| Shares Out (Mil) | 147.8 | 43.0 | 71% |
|
| Institutional Ownership | 5.5% | 84.3% | 6% |
|
| Float (Mil) | 97.1 | 46.8 | 61% |
|
| Beta | 1.99 | 0.62 | 92% |
|
| Avg Daily Volume (000s) | 3 | 285 | 11% |
|
| Price Change (52-week) |
(38.1%) | 63.8% | 20% |
|
| Growth | ADXN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (46.1%) | 6.7% | 0% |
|
| Net Income (5yr) | 10.1% | (1.4%) | 55% |
|
| EPS (5yr) | 32.0% | 14.9% | 82 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 47.0% | (14.9%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ADXN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $272 | 0% |
|
| Net Income (TTM) (Mil) | ($9) | ($11) | 30% |
|
| EPS (TTM) | ($0.077) | ($0.500) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($6) | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $5 | $522 | 6% |
|
| Valuation | ADXN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 173.33 | 2.73 | 100% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ADXN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (403.9%) | 65.9% | 1% |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (104.3%) | (24.6%) | 5% |
|
| ROE | (128.8%) | (19.7%) | 7% |
|
| Liabilities to Assets | 30.9% | 35.5% | 22% |
|
| F-Score | 1 | 3 | 1% |
|
Addex Therapeutics Ltd did not pass any screens on 7/31/2026.
